SkyePharma, Mundipharma to market Flutiform for asthma in Europe

By Lisa Kerner

Charlotte, N.C., Sept. 6 - SkyePharma plc and Mundipharma International Corp. Ltd. have agreed develop, market and distribute Flutiform, SkyePharma's novel combination product in a metered-dose aerosol inhaler for asthma and chronic obstructive pulmonary disease (COPD).

The agreement gives Mundipharma exclusive rights to market Flutiform in Europe and other territories outside North, Central and South America, with an option to negotiate for exclusive rights in Japan.

For its part, London-based SkyePharma received an upfront payment of $19 million, with expected milestone payments of up to $90 million and royalties.

"We expect to reach the market with Flutiform in 2009, by which time the European market for combination treatments for asthma and COPD is expected to exceed $3 billion," SkyePharma chief executive officer Frank Condella said in a company news release.

SkyePharma licensed Flutiform to Kos Pharmaceuticals, Inc. for the U.S. market.

Based in Bermuda, Mundipharma is one of the Purdue/Mundipharma/Napp pharmaceutical companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.